AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023
Oct 17, 2023
32254_dirs_2023-10-17_5d1b99d8-3f4c-41a1-ae7f-e7ddfe35f260.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-10-16
Reporting Person: Duty Stuart (N/A)
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7